Study of Bendamustine, Chidamide, and Lenalidomide Combination for Adults With Relapsed or Refractory Peripheral T-cell Lymphoma

What this Trial Is About

Researchers are studying the combination of bendamustine, chidamide, and lenalidomide to assess its effectiveness and safety in adults with relapsed or refractory peripheral T-cell lymphoma PTCL. This study focuses on patients who have previously received at least one systemic therapy and aims to evaluate outcomes such as complete response rate after treatment cycles. Participants will receive six 28-day cycles of the BCL regimen, with doses adjusted for patients over 70 years old. After four cycles, patients showing stable or progressive disease will leave the study, while those achieving partial or complete remission will continue with two more cycles. Afterwards, treatment diverges based on eligibility for autologous stem cell transplantation ASCT eligible patients undergo ASCT consolidation with conditioning therapy, while ineligible patients receive oral chidamide maintenance therapy for at least two years or until disease progression or unacceptable side effects. During the study, participants will be closely monitored through scans and laboratory tests to measure treatment response and safety. The primary outcome is the complete response rate after four cycles, with secondary outcomes including adverse events, overall response rate, and two-year survival and progression-free survival. Follow-up will continue up to two years after the last patients treatment, ensuring ongoing assessment of health and treatment effects throughout the study period.

Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients